3 results about "Types diseases" patented technology

The present invention relates to a quantitative analysis method for the influence of bridge diseases on structural performance, comprising the following steps: obtaining bridge information and regular inspection reports of the same type of bridges in a certain area; constructing a bridge structure analysis model according to the bridge information; extracting disease information from the regular inspection reports of the bridges, classifying the diseases into three categories: size attenuation type diseases, stiffness reduction type diseases and non-structural diseases, and the disease information including disease type, location, size and technical condition; at the same time, determining the structural analysis units affected by the diseases according to the disease locations and the node coordinates of the divided structural analysis units; calculating the relevant parameters after the influence of the diseases by using a correction model according to different types of diseases; correcting the element stiffness matrix with the relevant parameters after the influence of the diseases, integrating to obtain the global stiffness matrix S, and further obtaining the strain matrix d of the bridge. It solves the problem of the disconnection between disease information and structural analysis, and fills the gap between traditional disease qualitative assessment and SHM refined analysis.

The invention belongs to the technical field of biological pharmacy, and particularly discloses an LAG-3 and PD-L1 dual-targeting polypeptide and application thereof. The polypeptide P3E-D7 with high affinity to LAG-3 and PD-L1 is obtained through phage display peptide library screening and polypeptide structure optimization, the affinity of the polypeptide to LAG-3 and PD-L1 is high, and binding of LAG-3 / MHC-II and PD-1 / PD-L1 can be effectively blocked. The polypeptide coupled drug BsPep-IMDQ is obtained by coupling the polypeptide P3E-D7 and the imidazoquinoline IMDQ micromolecule drug, the toxic and side effects of the micromolecule drug can be effectively inhibited, polarization of M2 macrophages is inhibited, and activation of T cells is promoted, so that the growth of tumors is remarkably inhibited, and the polypeptide coupled drug has no obvious toxic and side effects and is suitable for clinical application. And a basis is provided for research and development of medicines for resisting tumors or other types of diseases.

The application discloses a 21-hydroxylase deficiency screening kit and application thereof, relates to the blood analysis technical field, and a steroid hormone marker composition of 21-hydroxylase deficiency, wherein the nine markers comprise 17alpha-hydroxyprogesterone, androstenedione, 11-deoxycortisol, 21-deoxycortisol, cortisol, corticosterone, progesterone, dihydrotestosterone and 11-deoxycorticosterone; the kit can be used for screening 21-hydroxylase deficiency, 11beta-hydroxylase deficiency, 17alpha-hydroxylase deficiency and other types of diseases; the kit comprises detection components for detecting the hormones; compared with a traditional time-resolved fluorescence immunoassay method, the LC-MS / MS multi-index combined detection scheme adopted in the application can significantly reduce false positive results; and invalid recall, unnecessary family anxiety and medical burden caused by false positive results are greatly reduced.